Prognostic role of plasma von Willebrand factor and soluble E‐selectin levels for future cardiovascular events in a ‘real‐world’ community cohort of patients with atrial fibrillation

Endothelial damage/dysfunction may contribute to a prothrombotic state in patients with atrial fibrillation (AF) and the increased risk of thromboembolism and cardiovascular events. Raised plasma von Willebrand factor (vWf), an established marker of endothelial damage/dysfunction, has been associated with stroke and vascular events, at least in a clinical trial population. Soluble E‐selectin (sE‐sel) is another biomarker of endothelial activation/dysfunction, with more limited data on prognostic outcomes in AF.

[1]  F. Marín,et al.  Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. , 2011, Journal of the American College of Cardiology.

[2]  G. Lip,et al.  Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients , 2009, Thrombosis and Haemostasis.

[3]  Timothy Watson,et al.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.

[4]  G. Lip,et al.  The endothelium and atrial fibrillation , 2008, Hämostaseologie.

[5]  G. Lip,et al.  Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. , 2008, International journal of cardiology.

[6]  G. Lip,et al.  Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. , 2008, Chest.

[7]  G. Lip,et al.  Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. , 2007, Chest.

[8]  A. Tveit,et al.  Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. , 2007, The American journal of cardiology.

[9]  G. Lip,et al.  Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation , 2006, Stroke.

[10]  G. Lip,et al.  Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation , 2003, Circulation.

[11]  G. Lip,et al.  Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. , 2000, Stroke.

[12]  G. Lip,et al.  The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[13]  P. Fasching,et al.  Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. , 1998, American journal of hypertension.

[14]  P. Fasching,et al.  Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[15]  A. Blann,et al.  A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION: DOES IT EXIST? , 1995, British journal of haematology.

[16]  G. Lip,et al.  Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. , 1995, British heart journal.

[17]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[18]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death , 1992, British heart journal.

[19]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[20]  Blann Ad.  von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. , 1991 .

[21]  D. Fass,et al.  Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. , 1986, The Journal of clinical investigation.

[22]  A. Chong,et al.  Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. , 2008, Thrombosis research.

[23]  A. Blann.  von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. , 1991, Zeitschrift fur Rheumatologie.

[24]  M. Blombäck,et al.  Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. , 1990, Stroke.